U.S. Revenue: $21 billion (down 12.5%)
Global Revenue: $21.9 billion (up 11%)
Top Brands: Copaxone ($4.2B), Treanda ($661M), ProAir ($565M), Qvar ($565M)
R&D Spend: $2.1B (up 38%), 10% of revenue
Upcoming Patent Expirations: Azilect, ProAir HFA
The 2016 headliner for Teva Pharmaceutical Industries was its acquisition of Actavis Generics, which sent $33.43 billion in cash and about 100 million Teva shares to Allergan. The deal secured a stronger command of the generics market, particularly in the U.S. However, the world’s leading generics company has watched stocks steadily plummet throughout the past 12 months, with shares trading at 10-year lows. Teva slashed $1 billion off the 2017 guidance released six months earlier, lowering its full-year sales forecast to somewhere between $23.8 billion and $24.5 billion. The announcement left analysts scratching their heads over the qualifications of Teva’s top-tier leaders, which was quickly followed by news of chief executive Erez Vigodman’s exit. Four patents for the firm’s top-seller Copaxone were ruled invalid in U.S. courts, thereby extending invitations to generic competitors of the MS medication. While revenue for Teva’s generic medicines unit grew 14% to $12 billion in 2016, the unit’s outlook is in question as the company joins an elite group of companies being investigated for U.S. price-fixing of generic drugs. Finally, Teva launched an authorized generic version of Minastrin 24 Fe1, an oral contraceptive developed by Allergan with about $325.9 million in U.S. sales in 2016.
